2023 World Conference on Lung Cancer (Posters)-P2.05. A Novel Autoantibodies Panel Predicted the Prognosis of Advanced Non-Small Cell Lung Cancer Receiving Anti-PD1 Combined With Chemotherapy

P2.05. A Novel Autoantibodies Panel Predicted the Prognosis of Advanced Non-Small Cell Lung Cancer Receiving Anti-PD1 Combined With Chemotherapy - PDF(Slides)

Back to course

Pdf Summary

This study aimed to identify a panel of novel autoantibodies (AAbs) that can predict the prognosis of advanced non-small cell lung cancer (aNSCLC) patients receiving chemoimmunotherapy. Chemoimmunotherapy has been shown to extend survival in aNSCLC patients, but resistance can develop in a significant proportion (30-40%) of patients. Currently, there is a lack of large-scale proteomic screening and multi-stage validation for prognostic AAbs in aNSCLC patients receiving chemoimmunotherapy.<br /><br />Between 2019 and 2022, plasma and formalin-fixed paraffin-embedded (FFPE) samples were collected from 271 aNSCLC patients. The study consisted of three phases: discovery, verification, and validation. In the discovery phase, a global plasma autoantibody profiling was conducted, and 241 candidate AAbs were selected for a focused array. In the verification phase, eight AAbs were found to be significantly different in responder and non-responder patients, and they were associated with survival outcomes in progression-free survival (PFS). In the validation phase, two AAbs were confirmed, and higher AAb levels were associated with superior outcomes in PFS.<br /><br />Furthermore, the study found that the levels of MAX AAb increased after treatment and declined during disease progression. This dynamic change in MAX AAb levels allowed the AAbs to predict prognosis both before and after treatment. Additionally, AAb-targeted mRNA and protein were found to be higher in aNSCLC patients with superior PFS.<br /><br />In conclusion, this study presents a panel of novel AAbs that can potentially predict the prognosis of aNSCLC patients receiving chemoimmunotherapy. These findings have implications for personalized treatment approaches and may help identify patients who are more likely to respond to chemoimmunotherapy. Further validation and clinical trials are needed to confirm these findings and establish their clinical utility.

Asset Subtitle

Liyuan Dai

Meta Tag

Speaker Liyuan Dai

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

autoantibodies

prognosis

advanced non-small cell lung cancer

chemoimmunotherapy

survival

resistance

plasma samples

formalin-fixed paraffin-embedded samples

progression-free survival

personalized treatment